S
Sarah E. Wilson
Researcher at University of Toronto
Publications - 82
Citations - 2572
Sarah E. Wilson is an academic researcher from University of Toronto. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 17, co-authored 54 publications receiving 1621 citations. Previous affiliations of Sarah E. Wilson include International Council for the Exploration of the Sea & York University.
Papers
More filters
Journal ArticleDOI
A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody Syndrome
Mark Crowther,Jeffrey S. Ginsberg,Jim A. Julian,Judah A. Denburg,Jack Hirsh,James D. Douketis,Carl A. Laskin,Paul R. Fortin,David C. Anderson,Clive Kearon,Ann E. Clarke,William Geerts,Melissa A. Forgie,David Green,Lorrie Costantini,Wendy Yacura,Sarah E. Wilson,Michael Gent,Michael J. Kovacs +18 more
TL;DR: The low rate of recurrent thrombosis among patients in whom the target INR was 2.0 to 3.0 suggests that moderate-intensity warfarin is appropriate for patients with the antiphospholipid antibody syndrome.
Journal ArticleDOI
Impaired Elastogenesis in Hurler Disease: Dermatan Sulfate Accumulation Linked to Deficiency in Elastin-Binding Protein and Elastic Fiber Assembly
Aleksander Hinek,Sarah E. Wilson +1 more
TL;DR: In this paper, it was shown that accumulation of dermatan sulfate but not heparan sulfates moieties is linked to impaired elastic fiber assembly that, in turn, contributes substantially to the development of the clinical phenotype in Hurler disease.
Journal ArticleDOI
Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario
Sharifa Nasreen,Hannah Chung,Siyi He,Kevin R. Brown,Jonathan B. Gubbay,Sarah A Buchan,Deshayne B. Fell,Peter C. Austin,Kevin L Schwartz,Maria E. Sundaram,Andrew Calzavara,Branson Chen,Mina Tadrous,Kumanan Wilson,Sarah E. Wilson,Jeffrey C. Long +15 more
TL;DR: The effectiveness of BNT162b2 (Pfizer-BioNTech Comirnaty), mRNA-1273 (Moderna Spikevax) and ChAdOx1 (AstraZeneca Vaxzevria) vaccines against symptomatic SARS-CoV-2 infection and COVID-19 hospitalization or death caused by the Alpha (B.1.7), Beta (B1.1), Gamma (P.1) and Delta (B 1.617.2) variants of concern (VOC) in Ontario, Canada, using a test-negative design study as mentioned in this paper .
Journal ArticleDOI
Low-Intensity Warfarin Is Ineffective for the Prevention of PTFE Graft Failure in Patients on Hemodialysis: A Randomized Controlled Trial
Mark Crowther,Catherine M. Clase,Peter J. Margetts,Jim A. Julian,Kim Lambert,Denise Sneath,Ryuta Nagai,Sarah E. Wilson,Alistair J. Ingram +8 more
TL;DR: In conclusion, low-dose warfarin was associated with an excess of clinically important major bleeding in patients with ESRD enrolled in this study, and low-intensity, monitored-dosewarfarin does not appear to prolong PTFE graft survival.
Journal ArticleDOI
Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes
Sarah A Buchan,Hannah Chung,Kevin R. Brown,Peter C. Austin,Deshayne B. Fell,Jonathan B. Gubbay,Sharifa Nasreen,Kevin L Schwartz,Maria E. Sundaram,Mina Tadrous,Kumanan Wilson,Sarah E. Wilson,Jeffrey C. Long +12 more
TL;DR: This case-control study estimates the effectiveness of COVID-19 vaccines against symptomatic infections due to the Delta and Omicron variants and severe outcomes associated with these infections among adults in Ontario, Canada.